<p>넥스트BT ( 065170 )<br>- 넥스트BT 지분 투자사 Rexahn사의 신약 Supinoxin™가 전임상에서 항암효과 확인.</p><p>외신) <br>Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition<br><a href="http://globenewswire.com/news-release/2015/12/14/795219/0/en/Rexahn-Pharmaceuticals-Announces-New-Data-for-Supinoxin-Showing-Potent-Tumor-Growth-Inhibition.html">http://globenewswire.com/news-release/2015/12/14/795219/0/en/Rexahn-Pharmaceuticals-Announces-New-Data-for-Supinoxin-Showing-Potent-Tumor-Growth-Inhibition.html</a><br>New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer</p><p>December 14, 2015 09:00 ET | Source: Rexahn Pharmaceuticals</p><p>ROCKVILLE, Md., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new preclinical data for its anti-cancer compound, Supinoxin™ (RX-5902) at the 38th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. </p><p>The Company’s presentation, entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Triple Negative Breast Cancer MDA-MB-231 Through Phosphorylated p68 on Tyr593” was co-authored by Frances Fuller-Pace, Ph.D., Division of Cancer Research, University of Dundee, United Kingdom and Rexahn scientists.</p><p> </p>
<!-- -->
